Elan To Spin Off Drug Discovery Business, Neotope Biosciences, By Yearend

What do you do when your drug discovery costs swamp your profits from a successful marketed drug.  If you’re Elan Corporation(ELN), you spin off your drug discovery business with a bundle of cash, keeping your marketed drugs and late stage pipeline. Elan, an Irish biotech firm, is driven largely by Tysabri,a multiple sclerosis drug marketed with Biogen Idec(BIIB).… Read More »